--- title: "Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of \"Moderate Buy\" from Analysts" type: "News" locale: "en" url: "https://longbridge.com/en/news/294380602.md" description: "Artiva Biotherapeutics (NASDAQ:ARTV) holds an average 'Moderate Buy' rating from six analysts, with a consensus 12-month price target of $39.00. Recent analyst actions include Needham setting a $41 target and Wedbush raising its to $40. Meanwhile, insiders Ra Capital Management and Corp. Gc significantly increased their stakes in May. Institutional investors like BNP Paribas also expanded positions. The company reported Q1 EPS of ($0.95), missing estimates." datetime: "2026-07-30T14:14:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294380602.md) - [en](https://longbridge.com/en/news/294380602.md) - [zh-HK](https://longbridge.com/zh-HK/news/294380602.md) --- # Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $39.00. Get **Artiva Biotherapeutics** alerts: Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Needham & Company LLC reiterated a "buy" rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Wedbush increased their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an "outperform" rating in a research note on Monday, May 11th. HC Wainwright raised their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a "buy" rating in a research report on Friday, May 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. **Check Out Our Latest Research Report on Artiva Biotherapeutics** ## Artiva Biotherapeutics Stock Performance ARTV traded up $0.09 during midday trading on Thursday, hitting $10.11. The company had a trading volume of 18,337 shares, compared to its average volume of 387,401. Artiva Biotherapeutics has a twelve month low of $2.22 and a twelve month high of $14.53. The company has a market capitalization of $249.92 million, a PE ratio of -2.86 and a beta of 2.18. The firm's 50-day simple moving average is $8.92 and its 200-day simple moving average is $7.45. Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, sell-side analysts anticipate that Artiva Biotherapeutics will post -2.45 EPS for the current fiscal year. ## Insider Activity In related news, Director Ra Capital Management, L.P. purchased 6,510,416 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $11.52 per share, with a total value of $74,999,992.32. Following the purchase, the director directly owned 15,203,995 shares in the company, valued at $175,150,022.40. The trade was a 74.89% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Corp. Gc purchased 1,085,069 shares of the business's stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $11.52 per share, for a total transaction of $12,499,994.88. Following the completion of the transaction, the insider directly owned 4,391,969 shares in the company, valued at $50,595,482.88. This trade represents a 32.81% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have bought 9,862,190 shares of company stock valued at $107,232,294 and have sold 53,040 shares valued at $477,890. 21.40% of the stock is currently owned by insiders. ## Institutional Trading of Artiva Biotherapeutics Large investors have recently made changes to their positions in the company. Qube Research & Technologies Ltd bought a new position in Artiva Biotherapeutics during the second quarter worth about $58,000. Marshall Wace LLP acquired a new stake in shares of Artiva Biotherapeutics during the second quarter worth about $79,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Artiva Biotherapeutics during the third quarter worth about $112,000. Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics during the 4th quarter valued at about $174,000. Finally, BNP Paribas Financial Markets grew its position in shares of Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company's stock valued at $340,000 after purchasing an additional 117,733 shares during the period. ## About Artiva Biotherapeutics (Get Free Report) Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches. Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors. ## See Also - Five stocks we like better than Artiva Biotherapeutics - 2 Unique Space ETFs That Could Upend the Industry - Corning Stock Crashes on Earnings, But the Sell-Off Looks Overdone - Palantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again - Mining For Megawatts: AMD's Billion-Dollar Grid Grab _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Artiva Biotherapeutics Right Now? Before you consider Artiva Biotherapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artiva Biotherapeutics wasn't on the list. While Artiva Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ARTV.US](https://longbridge.com/en/quote/ARTV.US.md) ## Related News & Research - [Iron Age Nutrition Full Product Line Now Available on Amazon](https://longbridge.com/en/news/296262447.md) - [CommVault Systems (NASDAQ:CVLT) CAO Sells 119 Shares](https://longbridge.com/en/news/296488416.md) - [Bit Origin To Implement 1-For-5 Reverse Stock Split To Meet Nasdaq Requirements](https://longbridge.com/en/news/296359463.md) - [Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays](https://longbridge.com/en/news/296230385.md) - [OrganiGram names Sanity co-founder Finn Age Hänsel president, rest of world and chief strategy officer](https://longbridge.com/en/news/296470062.md)